Marzia Capelletti

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/45866/publications.pdf

Version: 2024-02-01

65	12,093	94269 37	118652 62
papers	citations	h-index	g-index

66	66	66	17459
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing. Cell, 2012, 150, 1107-1120.	13.5	1,591
2	Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC. Cancer Cell, 2010, 17, 77-88.	7.7	956
3	Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neuâ€“Positive Metastatic Breast Cancer. Journal of Clinical Oncology, 2008, 26, 1789-1796.	0.8	940
4	Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature, 2009, 462, 1070-1074.	13.7	886
5	Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nature Medicine, 2012, 18, 382-384.	15.2	782
6	Crizotinib inALK-Rearranged Inflammatory Myofibroblastic Tumor. New England Journal of Medicine, 2010, 363, 1727-1733.	13.9	769
7	A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors. Cancer Research, 2011, 71, 6051-6060.	0.4	560
8	Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nature Medicine, 2013, 19, 1469-1472.	15.2	526
9	Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor. Cancer Cell, 2014, 26, 909-922.	7.7	376
10	EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors. Clinical Cancer Research, 2015, 21, 3913-3923.	3.2	318
11	The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers. Cancer Research, 2010, 70, 10038-10043.	0.4	306
12	Pooled Analysis of the Prognostic and Predictive Effects of KRAS Mutation Status and KRAS Mutation Subtype in Early-Stage Resected Nonâ€“Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy. Journal of Clinical Oncology, 2013, 31, 2173-2181.	0.8	270
13	Reactivation of ERK Signaling Causes Resistance to EGFR Kinase Inhibitors. Cancer Discovery, 2012, 2, 934-947.	7.7	255
14	Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial. Journal of Clinical Oncology, 2012, 30, 2063-2069.	0.8	225
15	Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 17041-17046.	3.3	225
16	KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS. Cell, 2018, 172, 857-868.e15.	13.5	220
17	Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer. Cancer Discovery, 2015, 5, 960-971.	7.7	211
18	Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nature Cancer, 2020, 1, 493-506.	5.7	209

#	Article	IF	Citations
19	Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene, 2010, 29, 2346-2356.	2.6	207
20	Inhibition of ALK, PI3K/MEK, and HSP90 in Murine Lung Adenocarcinoma Induced by EML4-ALK Fusion Oncogene. Cancer Research, 2010, 70, 9827-9836.	0.4	181
21	Resistance to Irreversible EGF Receptor Tyrosine Kinase Inhibitors through a Multistep Mechanism Involving the IGF1R Pathway. Cancer Research, 2013, 73, 834-843.	0.4	171
22	Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E4869-77.	3.3	154
23	A Functional Landscape of Resistance to ALK Inhibition in Lung Cancer. Cancer Cell, 2015, 27, 397-408.	7.7	150
24	Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer. British Journal of Cancer, 2010, 102, 1495-1502.	2.9	136
25	EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma. Clinical Cancer Research, 2012, 18, 1790-1797.	3.2	134
26	BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: A population-based study. Breast, 2007, 16, 280-292.	0.9	114
27	Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors. Cancer Research, 2017, 77, 2712-2721.	0.4	110
28	Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition. Cancer Research, 2015, 75, 4372-4383.	0.4	108
29	Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nature Communications, 2020, 11, 2996.	5.8	98
30	The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma. Cell Reports, 2017, 19, 218-224.	2.9	92
31	Identification of Recurrent FGFR3â€“TACC3 Fusion Oncogenes from Lung Adenocarcinoma. Clinical Cancer Research, 2014, 20, 6551-6558.	3.2	85
32	Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): Study of a comprehensive panel of molecular markers. Lung Cancer, 2010, 67, 355-360.	0.9	76
33	Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer. Clinical Cancer Research, 2017, 23, 204-213.	3.2	73
34	Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines. Biochemical Pharmacology, 2009, 78, 460-468.	2.0	71
35	Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer. Clinical Cancer Research, 2016, 22, 3148-3156.	3.2	71
36	Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2018, 24, 5963-5976.	3.2	63

#	Article	IF	Citations
37	Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors. Cancer Immunology Research, 2015, 3, 1333-1343.	1.6	42
38	Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow niche. Leukemia, 2018, 32, 1739-1750.	3.3	34
39	A Pooled Exploratory Analysis of the Effect of Tumor Size and KRAS Mutations on Survival Benefit From Adjuvant Platinum-Based Chemotherapy in Node-Negative Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 963-972.	0.5	33
40	Epidermal Growth Factor Receptor Intron-1 Polymorphism Predicts Gefitinib Outcome in Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2008, 3, 1104-1111.	0.5	32
41	Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2. Cancer Research, 2015, 75, 3139-3146.	0.4	30
42	Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients. Blood, 2018, 132, 2608-2612.	0.6	29
43	A breast cancer patient from Italy with germline mutations in both the BRCA1 and BRCA2 genes. Breast Cancer Research and Treatment, 2005, 91, 203-205.	1.1	24
44	Buccal Mucosa Cells as In vivo Model to Evaluate Gefitinib Activity in Patients with Advanced Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2007, 13, 6518-6526.	3.2	21
45	Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma. Leukemia, 2019, 33, 266-270.	3.3	21
46	Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T cell responses in a murine acute myeloid leukemia model. Haematologica, 2021, 106, 1330-1342.	1.7	19
47	Profiling of circulating exosomal miRNAs in patients with WaldenstrÃ¶m Macroglobulinemia. PLoS ONE, 2018, 13, e0204589.	1.1	17
48	Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations. Molecular Oncology, 2021, 15, 27-42.	2.1	15
49	Molecular Profile and Clinical Variables in Brca1-Positive Breast Cancers. A Population-Based Study. Tumori, 2005, 91, 505-512.	0.6	13
50	Whole-Exome Sequencing and Targeted Deep Sequencing of cfDNA Enables a Comprehensive Mutational Profiling of Multiple Myeloma. Blood, 2016, 128, 197-197.	0.6	8
51	The Role of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Multiple Myeloma: Immunomodulator Maintenance Post Autologous Stem Cell Transplant (ASCT) Predicts Better Outcome. Blood, 2018, 132, 749-749.	0.6	6
52	Characterization of GSTM3 polymorphism by real-time polymerase chain reaction with LightCycler. Analytical Biochemistry, 2004, 330, 175-177.	1.1	3
53	CD155-Tigit Pathway Modulation in Dendritic Cell/Acute Myeloid Leukemia Fusion Vaccine Model. Blood, 2019, 134, 1386-1386.	0.6	2
54	Development of Novel Second Generation DC/Tumor Fusion Vaccine in Lymphoma. Blood, 2019, 134, 392-392.	0.6	2

#	Article	IF	Citations
55	T Cells Educated By DC/AML Fusions in the Context of 4-1BB Costimulation As a Potent Strategy for Adoptive Cellular Therapy. Blood, 2019, 134, 2673-2673.	0.6	2
56	Driver Mutation in Waldenstrom's Macroglobullinemia and Their Clonal Heterogeneity during Progression and Relapse. Blood, 2016, 128, 1092-1092.	0.6	2
57	In Vivo Genome-Wide Crispr Library Screen in a Xenograft Mouse Model of Tumor Growth and Metastasis of Multiple Myeloma. Blood, 2016, 128, 1137-1137.	0.6	2
58	Refractory Pleural Small Cell Carcinoma in Never Smoker. A Case Report. Tumori, 2008, 94, 434-436.	0.6	1
59	Single-Cell RNA Sequencing Reveals Compromised Immune Microenvironment in Precursor Stages of Multiple Myeloma. Blood, 2018, 132, 2603-2603.	0.6	1
60	Profiling of Circulating Exosomes in Patients with WaldenstrÃ¶m Macroglobulinemia. Blood, 2016, 128, 2940-2940.	0.6	1
61	Potent Synergy between Combination of Chimeric Antigen Receptor (CAR) Therapy Targeting CD19 in Conjunction with Dendritic Cell (DC)/Tumor Fusion Vaccine in Hematological Malignancies. Blood, 2019, 134, 3227-3227.	0.6	1
62	Whole Exome Sequencing and Targeted Sequencing Reveal the Heterogeneity of Genomic Evolution and Mutational Profile in Smoldering Multiple Myeloma. Blood, 2016, 128, 237-237.	0.6	0
63	Microrna-138 Regulates Osteogenic Differentiation and Its Inhibition Presents a Novel Therapeutic Line to Prevent Bone Lytic Lesions in Multiple Myeloma. Blood, 2016, 128, 4483-4483.	0.6	0
64	Transcriptome Sequencing Demonstrates Unique Signature Associated with Durable Clinical Response to DC/AML Fusion Vaccine. Blood, 2019, 134, 3832-3832.	0.6	0
65	Synergism between CAR-T Cells and a Personalized Tumor Vaccine in Hematological Malignances. Blood, 2021, 138, 737-737.	0.6	0